INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

First Named Inventor Tianbi Art Unit Examiner Name Magda		10723002	
		2003-11-23	
		ing Brian Teng	
		2851	
		la Cruz	
		7293-056	

	U.S.PATENTS						Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	6169535		2001-01-02	Lee				
	2	6289735		2001-09-00	Dister et al				
	3	6967753		2005-03-00	Chinthammit et al				
	4	6974217		2005-12-13	Kmura				
If you wish	h to a	dd additional U.S. Pater	t citatio	n information pl	ease click the Add button.		Add		
U.S.PATENT APPLICATION PUBLICATIONS Remove									
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	20010000300		2001-04-00	Haile-mariam				
	2	20020063726		2002-05-30	Zhang et al				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10723002
Filing Date		2003-11-23
First Named Inventor Tianb		ing Brian Teng
Art Unit		2851
Examiner Name	Magda Cruz	
Attorney Docket Number		7293-056

Date Considered

	3	20020109668	2002	-08-15	Rosenberg et al				
	4	20030234797	2003	-12-25	Williams et al				
If you wis	h to a	dd additional U.S. Publi	shed Applicat	ion citatio	n information p	olease click the Ad	d butto	n. Add	
			FOR	EIGN PA	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Kind Code ² j Code		Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	TS
	1								
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add								
NON-PATENT LITERATURE DOCUMENTS Remove									
Examiner Initials*							Ţŝ		
	1								
If you wis	h to a	dd additional non-paten	t literature do	cument ci	tation informat	ion please click the	Add b	utton Add	_

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kint Code of USPTO Petert Documents at tense(ISPTO_COM) or MPEP 901.04. 2 Enter date that issued the document, by the two-letter code (WPC) Schadard S13.) 3 ** Suppasses plant for counters, the includation of the year of the region of the Emporar management between the replant document. ** Kind of document by the opportunities symbols as indicated on the document under WIPO Standard S11.6 if possible. ** Applicant is to place a check mark here if English tanguage streations in sattacted.

FXAMINER SIGNATURE

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10723002
Filing Date		2003-11-23
First Named Inventor	Tianbing Brian Teng	
Art Unit		2851
Examiner Name	Magd	a Cruz
Attorney Docket Number		7293-056

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 137(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ N=

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Graciela G. Cowger/	Date (YYYY-MM-DD)	2007-06-18
Name/Print	Craciala C. Causaar	Registration Number	42444

This collection of information is required by 3T CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Officer, U.S. perpartment of Commence, P. 0. Box 1450, Alexandria, V.3231-1450, D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the principal principal patients and the principal principal patients and the principal principal patients and the principal patients and the principal patients and the principal patients are patients. The principal patients are provided to the principal patients and the principal patients are patients. The principal patients are principally and the principal patients are principally as a patient of the patients and the principal patients are principally as a patient of the patients and the patients are provided to the patients and the patients are principally as a patient patients are principally as a patient patients and the patients are principally as a principal patient patients. The patients are patients are patients and the patients are patients and the patients are patients and the patients are patients. The patients are patients are patients are patients and the patients are patients and the patients are patients are patients. The patients are patients are patients are patients and the patients are patients are patients are patients. The patients are patients. The patients are patients are patients ar

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.